Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

OBJECTIVE: To determine reversion rates from chronic migraine to episodic migraine during long-term erenumab treatment. METHODS: A daily headache diary was completed during the 12-week, double-blind treatment phase of a placebo-controlled trial comparing erenumab 70 mg, 140 mg, and placebo, and week...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cephalalgia
المؤلفون الرئيسيون: Lipton, Richard B, Tepper, Stewart J, Silberstein, Stephen D, Kudrow, David, Ashina, Messoud, Reuter, Uwe, Dodick, David W, Zhang, Feng, Rippon, Gregory A, Cheng, Sunfa, Mikol, Daniel D
التنسيق: Artigo
اللغة:Inglês
منشور في: SAGE Publications 2020
الموضوعات:
Original Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7786390/
https://ncbi.nlm.nih.gov/pubmed/33269951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420973994
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة